Universe Pharmaceuticals INC: February 2025 SEC Form 6-K Highlights Key Shareholder Meeting

Here are the key insights extracted from the financial report:

1. Document Type and Filing:

• This is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC, indicating compliance with the Securities Exchange Act of 1934.

2. Company Information:

• Name: Universe Pharmaceuticals INC
• Address: 265 Jingjiu Avenue, Jinggangshan Economic and Technological Development Zone, Ji’an, Jiangxi, China 343100
• Contact Number: +86-0796-8403309

3. Reporting Period:

• The report is for the month of February 2025.

4. Extraordinary General Meeting:

• An extraordinary general meeting of shareholders was convened on February 17, 2025.
• The meeting was adjourned due to a lack of quorum and rescheduled for February 19, 2025, at 10:00 a.m. Beijing Time, at the same address.

5. Signatory:

• The report is signed by Gang Lai, who is the Chief Executive Officer of Universe Pharmaceuticals INC.
• The document is dated February 18, 2025.

6. Filing Options:

• The company indicates it files annual reports under Form 20-F and does not file under Form 40-F.

This report highlights key corporate governance actions (the adjournment of the extraordinary general meeting) and compliance with SEC filing requirements.